Document is current
Any future updates will be listed below
-
Authors
Fukuda, Koshiro https://orcid.org/0000-0003-0464-8923
Osumi, Hiroki https://orcid.org/0000-0002-4742-0446
Yoshinami, Yuri
Ooki, Akira https://orcid.org/0000-0001-7618-5775
Takashima, Atsuo
Wakatsuki, Takeru https://orcid.org/0000-0002-1463-3859
Hirano, Hidekazu https://orcid.org/0000-0003-1343-1419
Nakayama, Izuma https://orcid.org/0000-0003-4987-1934
Ouchi, Kota https://orcid.org/0000-0002-5572-1337
Sawada, Ryoichi https://orcid.org/0000-0003-2750-9141
Fukuoka, Shota https://orcid.org/0000-0001-9460-4486
Ogura, Mariko https://orcid.org/0000-0002-1004-8425
Takahari, Daisuke https://orcid.org/0000-0002-2492-6014
Chin, Keisho https://orcid.org/0000-0002-2015-8185
Shoji, Hirokazu https://orcid.org/0000-0002-8922-5227
Okita, Natsuko https://orcid.org/0000-0002-3990-5048
Kato, Ken https://orcid.org/0000-0002-1733-5072
Ishizuka, Naoki https://orcid.org/0000-0002-5856-9668
Boku, Narikazu https://orcid.org/0000-0002-1438-707X
Yamaguchi, Kensei https://orcid.org/0000-0001-6887-5709
Shinozaki, Eiji https://orcid.org/0000-0002-7448-5894
- License Information
-
More Information
Article History
Received: 6 April 2024
Accepted: 13 July 2024
First Online: 27 July 2024
Declarations
:
: This study was approved by the ethics review board of the Cancer Institute Hospital of the Japanese Foundation of Cancer Research (registry number 2021-GB-009) and was conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: The study protocol is described on the hospital website, and participants were provided with the opportunity to opt-out. No additional informed consent was obtained from any of the enrolled patients.
: Narikazu Boku received honoraria from ONO Pharmaceutical, Bristol Myers Squibb, Eli Lilly & Co, Daiichi Sankyo, and Taiho Pharmaceutical. Ken Kato received honoraria from ONO Pharmaceutical and Bristol Myers Squibb and consulting fees from ONO Pharmaceutical, Bristol Myers Squibb, BeiGene/Novartis, AstraZeneca, Roche, BAYER, Merck & Co, Merck bio, and Janssen. Hidekazu Hirano received honoraria from Bristol Myers Squibb, Chugai Pharma, Novartis, Taiho Pharmaceutical, Fujifilm, and Teijin Pharma and research funding from BeiGene.
